NRG-GY037

Open to Accrual

Return to Protocol Table

A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer

Principal Investigator

Jyoti Mayadev, MD

Co-Principal Investigator(s)

Dmitriy Zamarin, MD

Status

Open to Accrual

Date Opened To Accrual

September 29 2025

Disease Site

Gynecologic [GY]

Cervix

Phase

III

Developmental Therapeutics

Primary Objective

To determine whether induction IO and chemotherapy prior to CRT+IO improves progression-free survival (PFS) compared to CRT+IO alone.

Patient Population

Patients must have pathologically confirmed newly diagnosed cervical cancer. Eligible pathologic types: squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma.

Target Accrual

336

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Other

NRG-GY037 Study Overview Video by Dr. Jyoti Mayadev

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.